Q-omics provides the consensus-scored ABHD13 profile across patient tissues and cancer cell-line models. ABHD13 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ABHD13 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ABHD13 RNA expression shows 20,004 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KICH, and UVM as cancer lineages where ABHD13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD13 survival associations across molecular data types. ABHD13 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD13 RNA expression–survival associations across cancer types. High ABHD13 expression shows unfavorable associations in ACC, HNSC and UVM, but favorable associations in UCEC, KIRC and MESO. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for ABHD13 RNA expression.
This table summarizes ABHD13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ABHD13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD13 shows lower tumor expression in KICH, THCA, LUSC and LUAD and higher tumor expression in HNSC and STAD. The KICH box plot shows higher ABHD13 RNA expression in normal versus tumor tissue (log2 FC = −1.508, t-test p < 0.001).
This table shows molecular features associated with ABHD13 in patient tissues and cancer cell lines. In patient samples, ABHD13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ABHD13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
